Youzhiyou Bio is a bispecific antibody drug developer, specializing in the biopharmaceutical business centered on tumor immunotherapy, focusing on the research and development and industrialization of bispecific antibody drugs. It has successively developed CD3 double antibody products in 3 clinical stages including M802, M701, and Y150, and several preclinical research and development stages. Recently, Youzhiyou Bio completed 200 million C round of financing. This round of financing was completed by the joint investment of Wuhan Hi-Tech, Hubei Science and Technology Investment and Optics Valley Financial Holdings. Funds from this round of financing will be used for the clinical research and development of product pipelines including dual antibodies and new crown vaccines, and to accelerate the launch of products.
This article is reproduced from: https://www.itjuzi.com/investevent/13319456
This site is for inclusion only, and the copyright belongs to the original author.